1 active not recruiting, 1 recruiting. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow this condition Literature Review of Oligorecurrence trials Research Report on Oligorecurrence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response Adaptive radiotherapy using SBRT - Prostate Adenocarcinoma, Iliac Nodal Disease | Not applicable | Recruiting | University Health Network, Toronto | 26 | 2026-04-13 | 2026-10-20 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-10-19 |
Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Androgen Antagonists (1) · Flutamide (1) · Goserelin (1) · Leuprolide (1) · Methylprednisolone (1) · Prednisone (1) · Triptorelin Pamoate (1) · abiraterone (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · apalutamide (1) · bicalutamide (1) · enzalutamide (1) · histrelin (1) · nilutamide (1) · relugolix (1)
University Health Network, Toronto (1) · VA Office of Research and Development (1)
Canada (1) · United States (1)
I01CX002277 (1)